Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors
Novartis
Novartis
Gruppo Italiano Malattie EMatologiche dell'Adulto
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd.
Fate Therapeutics
Genentech, Inc.
Alexion Pharmaceuticals, Inc.
Pfizer
Novartis
University of Milano Bicocca
Celgene
Pharmacyclics LLC.
Celgene
M.D. Anderson Cancer Center
University Hospital Southampton NHS Foundation Trust
Newcastle University
University Hospital, Bordeaux
National Institutes of Health Clinical Center (CC)
GlaxoSmithKline
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
University of Pittsburgh
Novartis
Mirati Therapeutics Inc.
Dana-Farber Cancer Institute
Sanofi
Hospital Universitario Dr. Jose E. Gonzalez
University Hospital, Bordeaux
Pharmacyclics LLC.
Genta Incorporated
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Bristol-Myers Squibb
Ann & Robert H Lurie Children's Hospital of Chicago